Study Findings

Researchers at the aging⁤ Research Center (ARC) at Karolinska institutet have discovered a connection between kidney function and levels of ⁤blood-based ​biomarkers associated ​with ⁤Alzheimer’s disease. The study,published in Neurology,involved 2,279 ​individuals in Stockholm,Sweden,with an average age of 72. Participants were followed for‌ an average of ‍eight years, and ⁢none​ had dementia at the ‌study’s outset.

The ‌research team, led by assistant ⁣lecturer Giulia Grande, measured kidney function and levels⁤ of key proteins in ‍participants’ blood,⁣ including phosphorylated​ tau ‍proteins (specifically p-tau217), neurofilament light chain⁣ (NfL), and glial fibrillary acidic protein (GFAP). These ⁤biomarkers are increasingly used ‍to detect early indicators of neurodegeneration.

Kidney Function and Biomarker Levels

The study⁣ revealed ⁣that individuals ⁢with reduced kidney ‍function⁣ exhibited higher levels of most⁣ biomarkers, including p-tau217. However, diminished kidney function did *not* correlate‌ with an⁣ increased risk ⁤of developing dementia. Instead, ‍the data indicated​ that dementia symptoms tended to ⁣appear‌ earlier in individuals‍ with both elevated biomarker levels – particularly NfL ⁢- and impaired kidney ‌function.

This suggests ‌that kidney‍ health may influence *when* dementia symptoms manifest ⁣in ⁢those already ‍showing signs of brain​ changes,rather than ⁢directly ​causing the disease. The findings highlight the importance of considering kidney function when interpreting Alzheimer’s disease⁤ blood tests, especially in older adults.

Implications ‌for Alzheimer’s Research

The research, conducted by the Department of​ Neurobiology, Health‍ Sciences and Society at karolinska Institutet’s ⁣Aging Research‍ Center, underscores the⁣ complex interplay ‌between organ systems and neurodegenerative diseases. ⁣ Further inquiry is needed to fully ⁤understand the mechanisms linking kidney function and‍ Alzheimer’s biomarkers.